Potential for interactions between caspofungin and nelfinavir or rifampin.
about
Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactamsComparison of echinocandin antifungalsPopulation pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients.Human pharmacogenomic variations and their implications for antifungal efficacy.Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin.Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients.Drug-drug interactions of antifungal agents and implications for patient care.The safety of anidulafungin.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.The echinocandins.Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosisThe pharmacology and clinical use of caspofungin.The use of caspofungin in HIV-infected individuals.A comparative evaluation of properties and clinical efficacy of the echinocandins.Antifungal agents--clinical pharmacokinetics and drug interactions.Rifampin combination therapy for nonmycobacterial infections.Interactions between antifungal and antiretroviral agents.Caspofungin: when and how? The microbiologist's view.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Antifungal therapy in children: an update.Antifungal agents in current pediatric practice.Invasive fungal infections in the ICU: how to approach, how to treat.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Impact of special patient populations on the pharmacokinetics of echinocandins.Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes.Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infectionsPharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment.In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation.Pharmacology of Systemic Antifungal AgentsPharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins
P2860
Q24631021-C8E185CB-8443-4107-95AC-281E9CC6F10EQ28273738-3D132B1D-8EE2-4E93-B986-1C15A7FF25B8Q34932330-69272E94-AE0A-4062-BD27-58C273DA7D35Q35070838-01118149-B69A-4A68-A6A9-013DA3267137Q35666527-86EF3576-4BBE-4B5B-A4E8-A5FB787273B9Q35959489-4CB4E61E-D02F-46B6-B4E3-9B371996E3F8Q36176371-977B558F-4B2D-4CB8-A8AF-BF6FC90F9073Q36271648-E9685569-7E77-49F1-958E-DE4F150CF60FQ36283721-0916FDC7-01AF-49C1-AA47-E51A6B99D638Q36624970-0DC50689-588C-4B71-A809-B5B85E03E1A5Q36626518-F01FF1F1-7AAA-482A-8227-0C5E1E6DE29AQ36742397-A93C16F5-DBBA-481A-A07D-12E370BE0545Q36757591-FD002D7F-A825-4268-AE5B-DE002E445E6AQ36788428-EA846922-8683-4FC4-9699-C884ECFFCCAFQ36821383-F6C61D70-0A02-4735-8423-1D058E1D0E0DQ36895839-84BD0514-188B-476B-B0D3-C78E7E2910C4Q37159568-A7D0273C-4133-48EE-B9D2-1EB699638428Q37672039-730B906E-C3B5-4995-97E5-3A9C4260AE53Q37719545-B758CA43-3166-426D-A3D1-EFAAB05B3751Q37888750-FDA8567E-76B4-4E6D-83E9-1DE7C6DBBCC6Q37904672-5A3B8E2D-A2A9-42B2-9F33-7BDBC4A428F2Q38015090-57103CE3-D07B-4F17-AFB9-2248E8223A34Q38101520-02827B73-85FC-4BBB-863D-DB4107FF9D5EQ38180287-17D9BF6E-DD14-4386-A1EE-82DA3DEAE8BDQ38284468-723CA831-ABFC-4178-AAD9-2B6D24442334Q38462784-823B0F25-A1F0-4DEB-BB8D-6E38B5258983Q38586680-D93D13DA-A2E2-4401-B34D-3C543C412E50Q39701953-1DF12BD8-D051-4035-87D7-69F1E22018D8Q42257734-D6CA1228-92F7-4283-9880-4CFF500EB87EQ43169846-383CEE16-28A5-4E90-A7D1-CB3A56279D87Q46807629-B6432C37-95DD-41CF-BFA3-C66691E42C8EQ48301397-CAE219AE-1A31-42CE-BE51-5BE86F745D17Q54957028-40FF2CC2-1D9F-4BCF-AF45-F2B413B17DB7Q57533011-21D5F930-AADB-4B47-8F33-714BB844066EQ57746174-21A03F74-EB13-419E-AF90-6638D7B9D139
P2860
Potential for interactions between caspofungin and nelfinavir or rifampin.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Potential for interactions between caspofungin and nelfinavir or rifampin.
@en
type
label
Potential for interactions between caspofungin and nelfinavir or rifampin.
@en
prefLabel
Potential for interactions between caspofungin and nelfinavir or rifampin.
@en
P2093
P2860
P1476
Potential for interactions between caspofungin and nelfinavir or rifampin.
@en
P2093
Amanda Freeman
Elizabeth M Migoya
Gregory A Winchell
Howard Greenberg
Julie A Stone
Kalyan Ghosh
Kenneth C Lasseter
Lisa Hickey
Paul J Deutsch
Rajesh Desai
P2860
P304
P356
10.1128/AAC.48.11.4306-4314.2004
P407
P577
2004-11-01T00:00:00Z